Haematological Disorders Pregnancy and Childbirth
Conditions
Interventions
Daily ferrous sulphate group
Intermittent 60 mg of elemental ferrous sulphate
Sponsors
Okwara Ifeanyi Dickson
Eligibility
Sex/Gender
Female
Inclusion criteria
Inclusion criteria: oderate anaemic Packed cell volume (PCV) >19 % but < 25% pregnant women who are not underweight (BMI <18.55kg/m2 Reproductive aged women between 18 to 50 years Singleton pregnancy Women who have had previously normal first trimester blood work ( haematocrit), then develop moderate anaemia haematocrit level of 19% and 25%) later in the pregnancy. Women undergoing second and third trimester blood work from 12 to 32 weeks gestation with moderate anaemia Pregnant women with moderate anaemia designated with haematocrit (19% and 25%).
Exclusion criteria
Exclusion criteria: Women with medical problems known to affect iron metabolism or homeostasis Pregnant women without abnormal blood work indicating moderate iron deficiency anaemia Women with existing thalassemia or sickle cell anaemia Pregnant women already taking iron supplementation during pregnancy for treatment of iron deficiency anaemia Chronic illness is influencing moderate iron deficiency anaemia Those with history of bariatric surgery Underlying malabsorption disease Pregnant women with severe anaemia of Packed cell vlume level <18% Preterm labour, preterm premature rupture of membrane (PPROM), signs of infection Already participating in another study
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The primary outcome will be the change in Packed cell volume (PCV), and ferritin after 8 weeks of iron treatment. | — |
Secondary
| Measure | Time frame |
|---|---|
| Self reporting survey on compliance and of gastrointestinal adverse side effects such as vomiting, constipation, diarrhoea abdominal bloating after oral supplement. | — |
Countries
Nigeria
Contacts
Public ContactSamson Ejikunle
Consultant
Outcome results
None listed